Clinical Trial Update: Cilengitide in Treating Patients With Unresectable or Metastatic Melanoma [Phase 2]

View source ↗

Summary

A Phase 2 trial of cilengitide in patients with unresectable or metastatic melanoma was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• cilengitide (cilengitide)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Stage III Melanoma, Stage IV Melanoma | Phase 2 | Status: TERMINATED